Table 1.

Patient baseline characteristics

CharacteristicN = 25
Age, median (range), years53.0 (36–79)
Female, n (%)25 (100)
Race, n (%)
 White16 (64)
 Asian4 (16)
 Black or African American1 (4)
 Not specified4 (16)
ECOG performance status, n (%)
 013 (52)
 111 (44)
 Unknown1 (4)
Histology, n (%)
 Ductal carcinoma13 (52)
 Adenocarcinoma (NOS)6 (24)
 Lobular carcinoma3 (12)
 Carcinoid2 (8)
 Neuroendocrine1 (4)
LDH level, n (%)
 Normal11 (44)
 Elevated11 (44)
 Null3 (12)
Prior (neo)adjuvant therapy, n (%)17 (68)
Prior systemic therapies for metastatic disease, n (%)
 02 (8)
 11 (4)
 22 (8)
 34 (16)
 44 (16)
 ≥512 (48)
Type of prior therapy, n (%)a,b
 Chemotherapy25 (100)
 Endocrine therapy22 (88)
  Tamoxifen19 (76)
  Fulvestrant9 (36)
  Aromatase inhibitor17 (68)
 Other investigational therapy7 (28)
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NOS, not otherwise specified.

  • aPatients could have received ≥1 type of prior therapy.

  • bNot all prior therapies are listed.